Skip to main content

Articles By Jack Cush, MD

Covid lung pneumonia corona

Clinical Trial Boom or Bust in Severe COVID-19

By Jack Cush, MD
20 October 2020

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection. Remdesivir

Read Article
depression oh no HA

Biologic Use for Arthritis Linked With Depression and Anxiety

By Jack Cush, MD
20 October 2020

In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.

Read Article
shoulder.exam__0.jpg

Outpatient Visits Return to Pre-COVID Rates

By Jack Cush, MD
19 October 2020

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

Read Article
choices_0.jpg

TNF Inhibitors or non-TNF Biologics - First Best Choice?

By Jack Cush, MD
18 October 2020

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

By Jack Cush, MD
15 October 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
UPA ABA box

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

By Jack Cush, MD
15 October 2020

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.

Read Article
URI.infection.COrona_0.jpg

COVID Transmission from Young to Old

By Jack Cush, MD
13 October 2020

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Read Article
DVT.PE_.Blood__0.jpg

Tofacitinib and Thromboembolic Risk

By Jack Cush, MD
13 October 2020

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m

Read Article
Clot.DVT_.VTE_.blood_.jpg

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

By Jack Cush, MD
11 October 2020

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)  and that risk is linked to RA disease activity. 

Read Article
Plaquenil.HCQ_.pills_.jpg

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

By Jack Cush, MD
09 October 2020

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.

Read Article
×